Antibe Therapeutics, Inc. (Otc) (TSE:ATE) has released an update.
Antibe Therapeutics Inc. is set to present compelling safety and pharmacokinetic data for its non-opioid pain relief drug, otenaproxesul, at the upcoming ASRA Pain Medicine Meeting. The biotech firm is advancing its hydrogen sulfide-based platform, aiming to offer safer alternatives to traditional NSAIDs and opioids. Their lead drug, otenaproxesul, designed to reduce post-operative pain without the risk of abuse, will be highlighted by Chief Medical Officer Dr. Joseph Stauffer.
For further insights into TSE:ATE stock, check out TipRanks’ Stock Analysis page.
